secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0000950170-23-027742
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology shareholders elect three directors and ratify auditor
--------------------------------------------------------------------

- Rachel Humphrey, M.D. elected as Class I director: 13,536,830 for, 3,476,861 withheld, 10,500,726 broker non-votes.
- Freda Lewis-Hall, M.D. elected as Class II director: 13,597,586 for, 3,416,105 withheld, 10,500,726 broker non-votes.
- Thomas Civik elected as Class II director: 13,452,770 for, 3,560,921 withheld, 10,500,726 broker non-votes.
- Ratification of Ernst & Young LLP as FY2023 auditor passed: 27,404,246 for, 80,518 against, 29,653 abstain, no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023027742/0000950170-23-027742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023027742/pyxs-20230613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer